{"id":"NCT01362517","sponsor":"Crucell Holland BV","briefTitle":"Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B","officialTitle":"Assessment of the Immunogenicity and Safety of Quinvaxem Vaccine (DTwP-HepB-Hib) Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by H. Influenzae Among Healthy Vietnamese Children","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2010-07","completion":"2011-04","firstPosted":"2011-05-30","resultsPosted":"2013-06-24","lastUpdate":"2013-09-09"},"enrollment":131,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diphtheria","Pertussis","Tetanus","Hepatitis B","Haemophilus Influenzae Infections"],"interventions":[{"type":"BIOLOGICAL","name":"Quinvaxem","otherNames":[]}],"arms":[{"label":"Quinvaxem","type":"EXPERIMENTAL"}],"summary":"The aim of this study was to evaluate the immunogenicity and safety of the Quinvaxem vaccine (a liquid combination vaccine against diphtheria, tetanus, B. pertussis, hepatitis B and H. influenzae Type B). Healthy Vietnamese infants received three doses of vaccine at 2, 3 and 4 months of age according to the local Expanded Programme on Immunisation (EPI) schedule","primaryOutcome":{"measure":"Immunogenicity - Seroprotection (Seroconversion for Pertussis) to Each Vaccine Component","timeFrame":"at 5 months (equivalent to 1 month after the third vaccination)","effectByArm":[{"arm":"Quinvaxem","deltaMin":93.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"60 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":1,"countries":["Vietnam"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":131},"commonTop":["Pyrexia","Irritability","Injection site pain","Injection site induration","Diarrhea"]}}